Prostate Cancer Industry News & Blogs

Industry News & Blogs

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen
www.thelancet.com | Feb 13, 2012
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomis...

Utica Native Kevin Byrd advocacy work honored and entered into Congressional Record | PRLog
www.prlog.org | Feb 11, 2012
Utica Native Kevin Byrd advocacy work honored and entered into Congressional Record. Utica Native Kevin Byrd Youngest Prostate Cancer Advocate in U.S. and New Health & Wellness Chairman for the 100 work is honored by Congressional Record Honoring February 2, 2012 Prostate Cancer Awareness

FDA Questions Amgen Drug for Prostate Cancer
www.biospace.com | Feb 7, 2012
WASHINGTON — Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat

Trading Biotech In Pairs: A Better Way To Hedge - Seeking Alpha
seekingalpha.com | Feb 7, 2012
< strong > By < a href='http://seekingalpha.com/author/helix-investment-management' > Helix Investment Management < /a > : < /strong > < p > Biotechnology is both one of the most lucrative sectors in the market and the riskiest. The results of a single drug trial, or a single FDA decision, can

MabCure, Biotech Investment Co | MabCure signs license agreement with Biotech Investment Corp |
www.pharmaasia.com | Feb 7, 2012
MabCure has signed a license agreement with Biotech Investment Corp. (Biotech), a Nevada-based biotechnology investment company. The agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer. In addition to the license fee paid to

Hopkins Prostate Cancer Experts Available - 09/14/2010
www.hopkinsmedicine.org | Jan 27, 2012
September 19-25 is National Prostate Cancer Awareness Week. If you are planning a story on prostate cancer, a disease that’s diagnosed in more than 200,000 American men each year, please consider calling on experts from the Johns Hopkins Brady Urological Institute. With a variety of experts whose

Anti-Prostate Cancer Agent Orteronel(TAK-700) Enters into Phase III Clinical Trials in Japan
www.takeda.com | Jan 27, 2012
Osaka, Japan, Cambridge, Mass and Tokyo, Japan, January 27, 2012 – Takeda Pharmaceutical Company Limited (“Takeda”) and Millennium: The Takeda Oncology Company (“Millennium”) today announced that Takeda Bio Development Center Limited (“Takeda Bio”) has initiated enrollment of patients in Japan for

amednews: Stop giving PSA test to elderly, study urges :: Jan. 20, 2012 ... American Medical News
www.ama-assn.org | Jan 20, 2012
Annual screening leads to more cancer diagnoses but not fewer deaths, say researchers who followed more than 76,000 men for up to 13 years.

Age a big factor in prostate cancer deaths, study finds
www.sciencedaily.com | Oct 20, 2011
Contrary to common belief, men age 75 and older are diagnosed with late-stage and more aggressive prostate cancer and thus die from the disease more often than younger men, according to a new analysis.

Sinaiko Urology Announces Launch of HIFU Prostate Treatment Blog
www.prweb.com | Oct 20, 2011
Renown urologist, Peter Sinaiko, MD FACS, launches new blog to educate patients, medical professionals and regulators about the efficacy of HIFU therapy for treatment of prostate cancer. The blog is located at http://www.hifuprostatecancerdoctor.com.